• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Cardiovascular outcomes of dialysis patients using phosphate binders with or without calcium

byJames EnglandandAnees Daud
May 11, 2019
in Cardiology, Chronic Disease, Nephrology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this observational cohort study of patients with end-stage renal disease (ESRD) undergoing hemodialysis, there was no observed difference in cardiovascular events for patients receiving calcium-containing or calcium-free phosphate binders.

2. There was no difference in outcomes observed in pre-specified subgroup analysis based on sex or age group.

Evidence Rating Level: 2 (Good)

Study Rundown: High serum phosphate is a common complication of ESRD and is associated with increased cardiovascular mortality. Traditional methods to reduced phosphate levels include dietary changes and oral phosphate binders. The current Kidney Disease: Improving Global Outcomes (KDIGO) clinical guidelines recommend against calcium containing phosphate binders due to concern for calcium related cardiovascular disease. Non-calcium containing phosphate binders are costly, and evidence for reduction in cardiovascular outcomes compared to calcium containing agents is limited. This observational cohort study of Medicare patients with ESRD initiating dialysis who were on calcium acetate or the non-calcium binder sevelamer. The study found no difference in rates of cardiovascular events between the calcium and non-calcium groups, and no difference in overall survival.

The main strengths of the study included a broadly representative US population. The limitations of the study include the non-randomized design with potential for bias, and lack of data on PTH levels and use of iron-based phosphate binders, or over-the-counter calcium carbonate.

Click to read the study in JAMA Internal Medicine

Relevant Reading: Chronic Kidney Disease Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials

RELATED REPORTS

SGLT2 inhibitors reduce the risk of kidney disease in patients with and without diabetes

Personalized cooler dialysate does not reduce cardiovascular events for hemodialysis patients

Allopurinol does not reduce cardiovascular risk for patients with ischemic heart disease without gout

In-Depth [retrospective cohort]: This retrospective cohort study used data from United States Renal Data System (USRDS) and linked Medicare claims from May 1, 2012 – December 31, 2013. The study population included patients 65 years or older treated with sevelamer or calcium acetate within 180 days of initiating hemodialysis. Patients were excluded if they did not have ongoing dialysis, received transplant, had a history of alcohol use, previously used phosphate binders, or did not have phosphate/calcium levels measured during the study period. The primary outcome was hazard ratio for non-fatal cardiovascular events, while all-cause mortality was the secondary outcome.

The trial included 2639 patients receiving sevelamer, and 2065 receiving calcium acetate. The incidence rate of cardiovascular events was 458 per 1000 person-years for sevelamer and 464 per 1000 person-years for calcium acetate (HR 0.96; 95%CI, 0.84-1.10). There was no observed difference in overall mortality, or in analysis divided by age group, or sex.

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cardiovascular eventsend-stage renal disease (ESRD)hemodialysisphosphate binder
Previous Post

Mavacamten shows promise for treating patients with obstructive hypertrophic cardiomyopathy

Next Post

Quick Take: Association of socioeconomic status and brain injury with neurodevelopmental outcomes of very preterm children

RelatedReports

Tenofovir disoprovil fumarate HIV prophylaxis linked with minimal kidney impact
Chronic Disease

SGLT2 inhibitors reduce the risk of kidney disease in patients with and without diabetes

November 30, 2022
Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail
Cardiology

Personalized cooler dialysate does not reduce cardiovascular events for hemodialysis patients

November 23, 2022
Cardiology

Allopurinol does not reduce cardiovascular risk for patients with ischemic heart disease without gout

October 18, 2022
Nearly Half of All Pediatric Buprenorphine Exposures Result in Hospitalization
Cardiology

Polypill strategy reduces the risk of cardiovascular events after a myocardial infarction

September 15, 2022
Next Post
Increasing C-section room temperature linked to reduced neonatal, maternal hypothermia

Quick Take: Association of socioeconomic status and brain injury with neurodevelopmental outcomes of very preterm children

Stochastic resonance stimulation may decrease apnea of prematurity

Quick Take: Preterm birth and risk of chronic kidney disease from childhood into mid-adulthood: national cohort study

Quick Take: Opioid agonist treatment dosage and patient-perceived dosage adequacy, and risk of hepatitis C infection among people who inject drugs

Quick Take: Opioid agonist treatment dosage and patient-perceived dosage adequacy, and risk of hepatitis C infection among people who inject drugs

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Aspirin thromboprophylaxis noninferior to low-molecular-weight heparin in patients with fractures
  • Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia
  • Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options